Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Dhanvantri Jeevan Rekha Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 57.0 | 204.7 |
| Expenses | N/A | N/A |
| PBT | 1.5 | 2.6 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1.5 | 1.7 |
About Dhanvantri Jeevan Rekha Ltd.
| Founded | 1993 |
|---|---|
| Managing Director | Shalini Sharma |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,590.83 | 1,877.40 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,83,511.79 | 6,907.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,50,850.21 | 4,423.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,15,401.57 | 8,060.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,883.72 | 1,409.90 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,339.07 | 1,327.05 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,04,542.41 | 2,280.10 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,03,825.65 | 1,066.20 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,963.51 | 2,545.30 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 1,02,530.21 | 1,062.90 | 835.50 - 835.50 |
No Records Found
Latest News
Dhanvantri Jeevan Rekha submits board meeting intimation
Dhanvantri Jeevan Rekha informs about compliances-certificate
HealthCare Global Enterprises informs about statement of deviation or variation
Pursuant to the Listing Regulations, HealthCare Global Enterprises has confirmed that there were no deviations or variations in the utilisation of the proceeds raised through the Rights Issue of the Company during the quarter ended March 31, 2026, from the objects stated in the Letter of Offer dated February 24, 2026. In this regard, it has enclosed, as Annexure, the statement confirming that there was no deviation or variation in the utilisation of the aforesaid proceeds for the quarter ended March 31, 2026, from the objects stated in the Letter of Offer, in accordance with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019. The said statement has been duly reviewed by the Audit Committee of the Company. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/.
The above information is a part of company’s filings submitted to BSE.
Kopran - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 1180.39 | 759.35 | 55.45 | 3056.46 | 2710.10 | 12.78 | 3056.46 | 2710.10 | 12.78 |
| Other Income | 10.03 | 19.17 | -47.68 | 19.99 | 59.04 | -66.14 | 19.99 | 59.04 | -66.14 |
| PBIDT | 275.89 | 142.04 | 94.23 | 495.75 | 445.60 | 11.25 | 495.75 | 445.60 | 11.25 |
| Interest | 11.72 | 12.58 | -6.84 | 42.00 | 37.66 | 11.52 | 42.00 | 37.66 | 11.52 |
| PBDT | 264.17 | 129.46 | 104.06 | 453.75 | 407.94 | 11.23 | 453.75 | 407.94 | 11.23 |
| Depreciation | 13.44 | 12.39 | 8.47 | 49.81 | 49.99 | -0.36 | 49.81 | 49.99 | -0.36 |
| PBT | 250.73 | 117.07 | 114.17 | 403.94 | 357.95 | 12.85 | 403.94 | 357.95 | 12.85 |
| TAX | 63.28 | 31.09 | 103.54 | 99.94 | 89.38 | 11.81 | 99.94 | 89.38 | 11.81 |
| Deferred Tax | 5.45 | 3.74 | 45.72 | 9.58 | 3.06 | 213.07 | 9.58 | 3.06 | 213.07 |
| PAT | 187.45 | 85.98 | 118.02 | 304.00 | 268.57 | 13.19 | 304.00 | 268.57 | 13.19 |
| Equity | 482.86 | 482.86 | 0.00 | 482.86 | 482.86 | 0.00 | 482.86 | 482.86 | 0.00 |
| PBIDTM(%) | 23.37 | 18.71 | 24.95 | 16.22 | 16.44 | -1.35 | 16.22 | 16.44 | -1.35 |
Kwality Pharma - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 1568.22 | 1156.76 | 35.57 | 5030.59 | 3701.97 | 35.89 | 5030.59 | 3701.97 | 35.89 |
| Other Income | 10.58 | 7.65 | 38.30 | 28.59 | 19.20 | 48.91 | 28.59 | 19.20 | 48.91 |
| PBIDT | 397.96 | 266.64 | 49.25 | 1210.88 | 823.64 | 47.02 | 1210.88 | 823.64 | 47.02 |
| Interest | 28.87 | 24.92 | 15.85 | 109.70 | 98.78 | 11.05 | 109.70 | 98.78 | 11.05 |
| PBDT | 369.09 | 241.72 | 52.69 | 1092.89 | 724.86 | 50.77 | 1092.89 | 724.86 | 50.77 |
| Depreciation | 52.61 | 50.79 | 3.58 | 197.94 | 182.58 | 8.41 | 197.94 | 182.58 | 8.41 |
| PBT | 316.48 | 190.93 | 65.76 | 894.95 | 542.28 | 65.03 | 894.95 | 542.28 | 65.03 |
| TAX | 63.58 | 45.94 | 38.40 | 221.46 | 143.38 | 54.46 | 221.46 | 143.38 | 54.46 |
| Deferred Tax | -18.46 | -15.87 | 16.32 | -8.87 | -15.89 | -44.18 | -8.87 | -15.89 | -44.18 |
| PAT | 252.90 | 144.99 | 74.43 | 673.49 | 398.90 | 68.84 | 673.49 | 398.90 | 68.84 |
| Equity | 103.76 | 103.76 | 0.00 | 103.76 | 103.76 | 0.00 | 103.76 | 103.76 | 0.00 |
| PBIDTM(%) | 25.38 | 23.05 | 10.09 | 24.07 | 22.25 | 8.19 | 24.07 | 22.25 | 8.19 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dhanvantri Jeevan Rekha Ltd. is ₹19.70 as of 2026-05-19.
The market capitalisation of Dhanvantri Jeevan Rekha Ltd. is ₹8.07 as of 2026-05-19.
The 1-year return of Dhanvantri Jeevan Rekha Ltd. is 2.09% as of 2026-05-19.
The P/E ratio of Dhanvantri Jeevan Rekha Ltd. is 16.73 as of 2026-05-20.
The 52-week high and low of Dhanvantri Jeevan Rekha Ltd. are ₹35.86 and ₹16.55, respectively, as of 2026-05-19.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
